The collaboration envisages establishing a liquid biopsy platform for detecting Glioblastomas (GBM), one of the most aggressive malignant brain tumours in humans, a company statement said here.
Based on the diagnostic criteria provided by World Health Organization (WHO), Histopathological assessment has so far been considered the gold standard for identification of brain tumors.
However, the diagnosis procedure is not always precise due to substantial inter-observer variation, heterogeneous nature of tumors and complications arising from invasive cerebral biopsy. Management of GBMs remain challenging as there are no current curative treatments and therefore, mortality rates continue to stagnate at high levels, the statement said.
The project is the first of its kind in India. This clinical collaboration will pave the way towards development and deployment of exosome based diagnostics by providing clinicians a non-invasive tool for prognosis, diagnosis, cancer recurrence and therapy monitoring, the release said.